Follistatin and myostatin: protein, gene therapy, and claims
Understand follistatin’s role, the human gene-transfer research, and why it cannot validate retail “follistatin peptide” claims.
Explore myostatin inhibitor peptides, antibodies, and related proteins. Understand what each targets, what has been studied, and where the evidence stops.
Explore the compounds Compare the mechanismsConceptual overview. Different targets can produce different benefits and risks.
“Myostatin inhibitor peptides” is a broad search phrase. It often groups together substances with very different structures, targets, and evidence. A short peptide, an antibody, and a gene-transfer intervention are not interchangeable.
This reference starts with identity. Each profile explains the intervention, the type of evidence available, and the questions a reader should ask before drawing a conclusion.
Learn the molecular classes →Understand follistatin’s role, the human gene-transfer research, and why it cannot validate retail “follistatin peptide” claims.
Apitegromab is an antibody, not a short peptide. Read its SMA indication, activation-blocking mechanism, and current label context.
A guide to actual short-peptide research, its preclinical stage, and the gap between laboratory findings and human benefit.
Understand bimagrumab’s receptor target and why obesity trial results must be separated from claims about strength or short peptides.
Apitegromab-mstn, marketed as Isembyld, received a U.S. approval in September 2026 for a specific SMA population. Its label is an essential distinction when reading older pages that describe every myostatin inhibitor as unapproved.
Read the approval context →The same biological target does not make two interventions equivalent. Check the actual molecule, delivery method, study population, and measured result.
Use the research-quality guide →No. The category includes antibodies, receptor traps, binding proteins, and short experimental peptides. The compound’s structure and target matter. Start with the molecular class guide.
Choose the exact name in the article or claim you are checking. The compound library explains its class, relevant research, and the limits of that evidence.
No. The FDA approval of apitegromab-mstn applies to a defined SMA population and a specific medicine. It does not validate unrelated products. Read the apitegromab profile.